Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovelStem InternationalNSTM -26.36% Equity-to-Asset is -31.42 as of Jun. 2026. The stock has 3 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, NovelStem International ranks worse than 99.05% on this metric.
The historical rank and industry rank for NovelStem International's Equity-to-Asset or its related term are showing as below:
NSTM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -136.8 Med: -1.08 Max: 0.93
Current: -31.26
During the past 13 years, the highest Equity to Asset Ratio of NovelStem International was 0.93. The lowest was -136.80. And the median was -1.08.
NSTM's Equity-to-Asset is ranked worse than 99.05% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs NSTM: -31.26
NovelStem International (OTCPK:NSTM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
NovelStem International Equity-to-Asset Related Terms
NovelStem International Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSTM vs NOTVQ, PRPH, FUNI: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, NovelStem International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovelStem International Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where NovelStem International's Equity-to-Asset falls into.
NovelStem International Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
NovelStem International's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovelStem International (NSTM) has a Equity-to-Asset of -31.42 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on NovelStem International and its competitors. According to the industry distribution chart, NovelStem International ranks #209 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 99.1%.
Is NovelStem International's Equity-to-Asset too high?
NovelStem International's current Equity-to-Asset is -31.42. Based on the distribution chart, NovelStem International ranks #209 out of 211 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does NovelStem International's Equity-to-Asset compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #209 out of 211 companies for Equity-to-Asset. This places NovelStem International in the lower half of its industry. The industry median Equity-to-Asset is 0.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on NovelStem International and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovelStem International's current Equity-to-Asset is -31.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current Equity-to-Asset of -31.42. The current Equity-to-Asset is -31.42. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For NovelStem International (NSTM), the current Equity-to-Asset is -31.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSTM has been successfully added to your 
